NEOK Bio has taken a key step toward clinical development after the U.S. Food and Drug Administration approved its Investigational New Drug application for NEOK001, clearing the way for a Phase 1 clinical trial. The decision marks an important milestone for the oncology-focused biotech as it advances its first program into human studies and strengthens its position in the rapidly evolving antibody–drug conjugate (ADC) field.
NEOK001 is a first-in-class bispecific ADC designed to simultaneously target B7-H3 and ROR1, two cell-surface proteins that are highly expressed across a range of solid tumors. By engaging both targets, the therapy aims to improve tumor selectivity and enhance anti-cancer activity compared with traditional monovalent ADCs that bind to a single antigen. The antibody component of NEOK001 is linked to a potent topoisomerase I inhibitor payload through a specialized linker, allowing targeted delivery of the cytotoxic agent directly to cancer cells.
According to the company, preclinical studies of NEOK001 have demonstrated superior in vivo efficacy in multiple solid tumor models when compared with conventional ADC approaches. These findings suggest that dual-target engagement may translate into stronger tumor killing while potentially reducing off-target toxicity, a persistent challenge in ADC development.
With IND clearance in place, NEOK Bio plans to initiate a Phase 1 clinical trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of NEOK001 in patients with cancers that co-express B7-H3 and ROR1. The company expects to dose the first patient in the coming months and anticipates sharing initial clinical data in 2027.
NEOK Bio was launched last year with backing from ABL Bio, a global leader in antibody engineering technologies. The company was established to build a pipeline of differentiated bispecific ADCs that leverage advanced antibody design to improve therapeutic outcomes for cancer patients. NEOK001 is the first asset from this platform to reach the clinic, underscoring the company’s focus on next-generation ADC innovation.
Company leadership described the IND approval as a validation of NEOK Bio’s scientific strategy and its commitment to addressing significant unmet needs in oncology. As competition intensifies in the ADC space, NEOK Bio aims to differentiate itself through bispecific targeting approaches that could expand the therapeutic potential of ADCs in solid tumors.